keyboard_arrow_up

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Pipeline Review, H1 2015

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2015 provides comprehensive information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and special features on late-stage and discontinued projects. Get a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=403522 . (This is a premium report price at US$2500 for a single user PDF license)

Some of the Company profiles mentioned in this report are Acetylon Pharmaceuticals, Altor BioScience Corporation, Aptose Biosciences Inc, Bio-Path Holdings, Cancer Therapeutics CRC Pty Ltd, Constellation Pharmaceuticals, Esperance Pharmaceuticals, Formula Pharmaceuticals, Genzyme Corporation, Jasco Pharmaceuticals, Kinex Pharmaceuticals, Onyx Pharmaceuticals.

Scope

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in the therapeutics development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type

The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.